Payment overview · 2025
General Payments
$589.99
39 reported records · 7 companies
Healthcare provider profile · identity verified
John Vernon Barton, MD
Allopathic & Osteopathic Physicians|Emergency Medicine · SLIDELL, LA · NPI 1841233095
Verified facts
What the public records show
CMS Open Payments records show John Vernon Barton, MD received $589.99 in general payments during 2025 across 39 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trintellix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $231.46 | 39.2% | 19 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $184.59 | 31.3% | 11 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $51.81 | 8.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.03 | 7.0% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.43 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.55 | 4.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.12 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $589.99 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $231.46 | 19 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $184.59 | 11 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $51.81 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $41.03 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.03 | 2 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.55 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 81 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
38 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 545 | 71 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 334 | 42 |
| Gabapentin | Gabapentin | 245 | 52 |
| Alprazolam | Alprazolam | 227 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 227 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 32 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 124 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 32 |
| Methylprednisolone | Methylprednisolone | 117 | 75 |
| Omeprazole | Omeprazole | 112 | 31 |
| Tramadol Hcl | Tramadol Hcl | 110 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 33 |
| Potassium Chloride | Potassium Chloride | 105 | 31 |
| Lisinopril | Lisinopril | 100 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 96 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 24 |
| Ibuprofen | Ibuprofen | 92 | 20 |
| Ozempic | Semaglutide | 90 | 15 |
| Clonazepam | Clonazepam | 89 | 12 |
| Mounjaro | Tirzepatide | 81 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 80 | 26 |
| Metformin Hcl | Metformin Hcl | 75 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 18 |
| Furosemide | Furosemide | 72 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 19 |
| Ondansetron Odt | Ondansetron | 71 | 24 |
| Pregabalin | Pregabalin | 71 | 14 |
| Meloxicam | Meloxicam | 69 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 13 |
| Diazepam | Diazepam | 64 | 17 |
| Promethazine Hcl | Promethazine Hcl | 64 | 16 |
| Enalapril Maleate | Enalapril Maleate | 63 | 21 |
| Levofloxacin | Levofloxacin | 63 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | suppressed |
| Celecoxib | Celecoxib | 60 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | suppressed |
| Allopurinol | Allopurinol | 54 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 53 | 11 |
| Azithromycin | Azithromycin | 52 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Losartan Potassium | Losartan Potassium | 48 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 22 |
| Fluconazole | Fluconazole | 47 | 24 |
| Famotidine | Famotidine | 46 | 16 |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Temazepam | Temazepam | 44 | 12 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Estradiol | Estradiol | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 20 |
| Trintellix | Vortioxetine Hydrobromide | 38 | 16 |
| Baclofen | Baclofen | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 13 |
| Linzess | Linaclotide | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 11 |
| Atenolol | Atenolol | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $589.99 · 39 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AREXVY, AZMIRO, Auvelity, CAPLYTA, MOUNJARO, SHINGRIX, TRINTELLIX, VOQUEZNA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error